[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"memory-problems\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:memory-problems":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100630244","a-study-to-compare-two-different-sleep-tests-in-participants-with-no-symptoms-or-early-symptoms-of-alzheimers-disease-100630244",false,"NCT07485153","A Study to Compare Two Different Sleep Tests in Participants With No Symptoms or Early Symptoms of Alzheimer's Disease","A Study to Assess the Use of the Somfit, an Ambulatory Electroencephalogram-Based Digital Health Technology, Compared With Polysomnography to Evaluate Sleep Architecture in Individuals With Asymptomatic or Early Alzheimer's Disease","Inclusion Criteria:\n\n* Have mild cognitive impairment, subjective memory complaints, or normal cognition.\n* Evidence of the presence of Alzheimer's pathology as measured by amyloid positron emission tomography (PET), cerebrospinal fluid biomarkers (amyloid beta and tau), or blood biomarkers.\n* Montreal Cognitive Assessment (MoCA) score of 24 or greater.\n* Clinical Dementia Rating Scale (CDR) global score of 0 or 0.5.\n* Able to provide signed informed consent.\n* On stable medications (including those for Alzheimer's disease) for 30 days before the first recording night of Study Period 1, and willing to remain on stable therapy during the study.\n* Must have a study partner who knows the participant well and can accompany the participant at visits where informant-rated scales are administered.\n\nExclusion Criteria:\n\n* Severe illness that in the investigator's judgement would adversely affect the participant's participation in the study.\n* Skin illness that may interfere with study assessments.\n* Has a pacemaker or implantable cardioverter defibrillator.\n* Diagnosed with a sleep disorder.\n* Has irregular circadian patterns (works night shifts, etc.).\n* Is pregnant or lactating\u002Fbreastfeeding at time of screening.\n* Use of sleep aid medications (such as melatonin, Ambien, Lunestra) or other medications or substances that could affect sleep (alcohol, cannabinoids, or opioids) on nights of in-clinic and at-home recordings.\n* Currently enrolled in another clinical study involving an investigational product or other type of medical research judged not to be scientifically or medically compatible with this study.\n* People who habitually spend less than 5 hours in bed per night.\n* No alcohol will be allowed at least 24 hours before the use of the EEG and throughout the clinical assessment period.","ALL","55 Years","85 Years",{"count":20,"type":21},35,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to compare the results of two different sleep tests in Alzheimer's patients with no symptoms or early symptoms. Participants will undergo two simultaneous sleep tests (polysomnography) in a sleep laboratory for two nights and one sleep test at home for three nights. For each participant, the study will last at least a week and will last up to three months.",[25,26,27],"Alzheimer's Disease","Early Alzheimer's Disease","Memory Problems","NOT_YET_RECRUITING","2026-03-17",{"date":31,"type":32},"2026-03-20","ACTUAL",{"date":34,"type":21},"2026-03",{"date":36,"type":21},"2026-09",{"name":38,"class":39},"Eli Lilly and Company","INDUSTRY",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":48,"sex":16,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":69,"locationsCount":40},"100595618","a-clinical-trial-to-examine-lysoveta-on-cognitive-function-in-healthy-adults-with-self-perceived-memory-problems-100595618","NCT07034794","A Clinical Trial to Examine Lysoveta on Cognitive Function in Healthy Adults With Self-perceived Memory Problems","A Randomized, Triple-blind, Placebo Controlled, Parallel Clinical Trial to Examine Lysoveta on Cognitive Function in Healthy Adults With Self-perceived Memory Problems","Inclusion Criteria:\n\n1. Males and females between 50 and 75 years, inclusive\n2. Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening\n\n   Or,\n\n   Individuals of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:\n   * Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)\n   * Double-barrier method\n   * Intrauterine devices\n   * Non-heterosexual lifestyle and agrees to use contraception if planning on changing to heterosexual partner(s)\n   * Vasectomy of partner at least 6 months prior to screening\n   * Abstinence and agrees to use contraception if planning on becoming sexually active during the study\n3. Self-reported memory problems as assessed by a combined score of ≥ 6 on Everyday Memory Questionnaire (EMQ) questions 1, 2 and 18 at screening\n4. Agrees to avoid moderate-vigorous exercise 12 hours prior to post-screening clinic visits\n5. Agrees to avoid high sources of caffeine (e.g., supplements, tea, coffee, energy drinks), NSAIDs, and alcohol consumption for 24 hours prior to post-screening clinic visits\n6. Agrees to avoid first generation anti-allergy medication for 48 hours prior to post-screening clinic visits\n7. Agrees to maintain current lifestyle habits (diet, physical activity, medications, supplements, and sleep) as much as possible throughout the study\n8. Agrees to avoid travelling between two or more time zones within one week of in-clinic visits\n9. Willingness to complete questionnaires, records and diaries associated with the study and to complete all clinic visits\n10. Provided voluntary, written, informed consent to participate in the study\n11. Healthy as determined by medical history and laboratory results as assessed by Qualified Investigator (QI)\n\nExclusion Criteria:\n\n1. Individuals who are pregnant, breast feeding, or planning to become pregnant during the study\n2. Allergy, sensitivity, or intolerance preventing consumption of investigational product or placebo ingredients, including seafood and\u002For shellfish\n3. Dementia or other significant cognitive impairment as assessed by the Mini Mental State Exam-2 Standard Version (MMSE-2) with a score \\\u003C 24 at screening\n4. Self-reported confirmation of any significant neuropsychological condition and\u002For cognitive impairment (e.g., Schizophrenia, bipolar disorder, post-traumatic stress disorder, brain injury, neurodegenerative disease, infections, insomnia, depression, epileptic or other seizure-related disorders) that could interfere with study participation as assessed by the QI\n5. Regularly consumes two or more servings of fatty fish per week as assessed by the QI\n6. Self-reported color blindness\u002Fweakness as assessed by the QI\n7. Current employment that calls for overnight shiftwork as assessed by the QI\n8. Postmenopausal confusion, as assessed by the QI\n9. Unstable metabolic disease or chronic diseases as assessed by the QI\n10. Current or history of any significant diseases of the gastrointestinal tract as assessed by the QI\n11. Unstable hypertension. Treatment on a stable dose of medication for at least 3 months will be considered by the QI (See Section 7.3)\n12. Type I diabetes\n13. Type II diabetes if on insulin treatment. Type II diabetics on stable medication for at least three months and an HbA1c of \\\u003C8.0% may be included after assessment by the QI on a case-by-case basis\n14. Significant cardiovascular event in the past 6 months. Participants with no significant cardiovascular event on stable medication may be included after assessment by the QI on a case-by-case basis\n15. History of or current diagnosis with kidney and\u002For liver diseases as assessed by the QI on a case-by-case basis, with the exception of history of kidney stones in participants who are symptom free for 6 months\n16. Self-reported confirmation of current or pre-existing thyroid condition. Treatment on a stable dose of medication for at least 3 months will be considered by the QI\n17. Major surgery in the past 3 months or individuals who have planned surgery during the course of the study. Participants with minor surgery will be considered on a case-by-case basis by the QI\n18. Cancer, except skin basal cell carcinoma completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable\n19. Individuals with an autoimmune disease or are immune compromised as assessed by the QI\n20. Self-reported confirmation of a HIV-, Hepatitis B- and\u002For C-positive diagnosis as assessed by the QI\n21. Self-reported confirmation of blood\u002Fbleeding disorders as assessed by the QI\n22. Use of medical cannabinoid products\n23. Chronic use of cannabinoid products (\\>2 times\u002Fweek). Occasional users will be required to washout and abstain for the duration of the study period\n24. Irregular use of tobacco or nicotine products in the past one month, as assessed by the QI\n25. Alcohol intake average of \\>2 standard drinks per day as assessed by the QI\n26. Alcohol or drug abuse within the last 12 months\n27. Current use of prescribed and\u002For over-the-counter (OTC) medications, supplements, and\u002For consumption of food\u002Fdrinks that may impact the efficacy or safety of the investigational product (Section 7.3)\n28. Clinically significant abnormal laboratory results at screening as assessed by the QI\n29. Blood donation 30 days prior to baseline, during the study, or a planned donation within 30 days of the last study visit\n30. Participation in other clinical research studies 30 days prior to baseline, as assessed by the QI\n31. Individuals who are unable to give informed consent\n32. Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant",true,"50 Years","75 Years",{"count":52,"type":21},138,"INTERVENTIONAL",[55],"NA","The study is a randomized, placebo-controlled, triple-blind, parallel group trial, in which the effect of krill oil is investigated in healthy volunteers with self-perceived memory problems. Volunteers are randomly allocated to the 2 study groups including placebo and Lysoveta. Over the whole study period, volunteers will be asked to complete questionnaires to evaluate cognitive performance and mood throughout the duration of the trial.\n\nThe goal of this clinical trial is to examine Lysoveta on cognitive function in healthy adults with self-perceived memory problems. The main question it aims to answer is:\n\nWhat is the difference in change in episodic, working and spatial memory as assessed by the Computerized Mental Performance Assessment System (COMPASS) between Lysoveta and placebo?",[58,27],"Healthy",[60,27,61],"Lysoveta","Hydrolyzed krill oil","RECRUITING","2026-01-08",{"date":65,"type":32},"2026-01-09",{"date":67,"type":32},"2025-12-06",{"date":36,"type":21},{"name":70,"class":39},"Aker BioMarine Human Ingredients AS"]